FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Marizyme, Inc. Stock AnalysisComprehensive stock analysis for Marizyme, Inc. (MRZM) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisMRZM
MRZM
Marizyme, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
MRZM
Home🔹Stocks🔹Marizyme, Inc.

Marizyme, Inc.

MRZM•OTC

Marizyme, Inc.

MRZM•OTC
Market cap
$39.54K
Sentiment

Your view on MRZM

Mkt Cap
$39.54K
Sentiment
Your view
MRZM
Marizyme, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
MRZM
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Marizyme, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
David L. Barthel
Headquarters
555 Heritage Drive, Jupiter, FL, US
Industry
Biotechnology
Sector
Healthcare
CEO
David L. Barthel
Headquarters
555 Heritage Drive, Jupiter, FL, US
Description

Marizyme, Inc., a life science company, engages in the development and commercialization of medical technologies business. It offers DuraGraft, a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, and other related properties. The company also develops various products using its Krillase protease-based therapeutic platform for treating complex wounds and burns, acute ischemic stroke, deep vein thrombosis, and dissolving plaque and biofilms on teeth. In addition, it focuses on developing products to mitigate the effects of ischemia reperfusion injury in other grafting and transplantation surgeries, and other indications. Further, it is involved in developing MATLOC, a point-of-care, lab-on-chip digital screening and diagnostic device platform for chronic kidney disease assessment. The company was formerly known as GBS Enterprises Incorporated. Marizyme, Inc. was incorporated in 2007 and is based in Jupiter, Florida.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News